CorrectSequence Therapeutics

CorrectSequence Therapeutics is a pioneering biopharmaceutical company that, since its establishment in 2020, has made significant breakthroughs in base editing technology. The company's mission, encapsulated in the slogan "Correct the Gene, Enlighten the Future," underscores its dedication to using innovative base editing systems to address severe diseases. Recent funding of CNY300.00M through a Series A investment in November 8, 2021, involving key investors such as Lilly Asia Ventures, New Alliance Capital, Boyu Capital, Sequoia China, TF Capital, and Zoo Capital, reflects strong support and confidence in its potential. Through its cutting-edge base editing technology, CorrectSequence Therapeutics has demonstrated superior control over off-target effects and enhanced in vivo editing efficiency. Notably, the company's base editing studies have been featured in renowned scientific journals, including Nature Biotechnology, Nature Cell Biology, Nature Structural & Molecular Biology, Cell Research, and Cell Reports. Operational centers in Shanghai and China Central Place, Beijing, coupled with a world-class R&D laboratory and cGMP manufacturing facility, underscore the company's commitment to rapidly translating innovative research into tangible applications. With a diverse pipeline encompassing genetic diseases, cancer immunotherapy, metabolic diseases, and infectious diseases, the CorrectSequence Therapeutics is positioned to contribute significantly to advancing biotechnological innovation and addressing unmet medical needs.